Osteosarcoma (OS) is an aggressive pediatric cancer with unmet therapeutic needs. Glutaminase 1 (GLS1) inhibition, alone and in combination with metformin, disrupts the bioenergetic demands of tumor progression and metastasis, showing promise for clinical translation. Three positron emission tomography (PET) clinical imaging agents, [F]fluoro-2-deoxy-2-D-glucose ([F]FDG), 3'-[F]fluoro-3'-deoxythymidine ([F]FLT), and (2S, 4R)-4-[F]fluoroglutamine ([F]GLN), were evaluated in the MG63.3 human OS xenograft mouse model, as companion imaging biomarkers after treatment for 7 d with a selective GLS1 inhibitor (CB-839, telaglenastat) and metformin, alone and in combination. Imaging and biodistribution data were collected from tumors and reference tissues before and after treatment. Drug treatment altered tumor uptake of all three PET agents. Relative [F]FDG uptake decreased significantly after telaglenastat treatment, but not within control and metformin-only groups. [F]FLT tumor uptake appears to be negatively affected by tumor size. Evidence of a flare effect was seen with [F]FLT imaging after treatment. Telaglenastat had a broad influence on [F]GLN uptake in tumor and normal tissues. Image-based tumor volume quantification is recommended for this paratibial tumor model. The performance of [F]FLT and [F]GLN was affected by tumor size. [F]FDG may be useful in detecting telaglenastat's impact on glycolysis. Exploration of kinetic tracer uptake protocols is needed to define clinically relevant patterns of [F]GLN uptake in patients receiving telaglenastat.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623067 | PMC |
http://dx.doi.org/10.1089/cbr.2022.0090 | DOI Listing |
Heliyon
January 2025
Programa de Pós-Graduação em Medicina Veterinária - Clínica e Reprodução Animal, Universidade Federal Fluminense, Niterói, RJ, Brazil.
Feline primary bone tumors are rare. Still, osteosarcoma (OSA) composes almost 80 % of malignant bone tumors in cats, affecting mostly elder feline individuals. Many differences are observed between canine and feline OSA regarding radiographic image and tumoral behavior, especially metastasis development.
View Article and Find Full Text PDFTrials
January 2025
Department of Traditional Chinese Medicine, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518033, Guangdong, P. R. China.
Background: The aim of this study is to evaluate the efficacy and safety of diacylglycerol (DAG) edible oil intervention in patients with chronic metabolic syndrome complicated by asymptomatic hyperuricemia through a multicenter, prospective, double-blind, randomized controlled clinical trial.
Methods: A multicenter, double-blind, and randomized controlled trial involving 176 patients was designed. All patients with chronic metabolic syndrome complicated by asymptomatic hyperuricemia who meet inclusion and exclusion criteria will be included in the study and will be randomized to either group A or group B.
Cardiovasc Diabetol
January 2025
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Università degli Studi di Milano, Milano, Italy.
Background: The triglyceride-glucose (TyG) index is now widely recognized as a marker of insulin resistance and has been linked to the development and prognosis of atherosclerotic cardiovascular diseases (ASCVD) in numerous populations, particularly in the Eastern world. Although there are fewer reports from the Western world, and they are sometimes contradictory, the absence of definitive data on the relationship between a raised TyG index and cardiovascular risk suggested the opportunity of testing this biochemical marker against a well-established vascular marker such as the carotid intima media thickness (c-IMT).
Methods: Primary prevention patients were selected from a cohort of individuals who underwent c-IMT measurement between 1984 and 2018 at the Dyslipidemia Center at the ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy.
Cardiovasc Diabetol
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and/or abnormal cardiac biomarker concentrations.
Objective: To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.
Background: Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD).
Methods: For the purpose of identifying butyrate metabolism-related differentially expressed genes (BMR-DEGs) in the TCGA-LUAD dataset, we introduced transcriptome data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!